Health Information Services
SAGILITY LIMITED (NSE: SAGILITY) clears resistance, moves up 5% intraday
SAGILITY LIMITED (NSE: SAGILITY) stock price moves up 5% intraday, clearing its 6-month resistance trendline at ₹42.77.
SAGILITY LIMITED (SAGILITY) breaks out with a +5% gain to ₹42.77 on the NSE today, clearing its 6M resistance trendline. This move follows the company’s announcement of a Certificate under SEBI (Depositories and Participants) Regulations, 2018. SAGILITY, a player in the Healthcare > Health Information Services sector, has shown resilience despite sector-wide pressures, indicating a company-specific catalyst driving today’s performance.
Technical setup — trendlines & DMA
The current 6M trendline structure shows SAGILITY comfortably above its support at ₹38.3, currently trading 10.45% higher. Resistance was previously at ₹42.13, which the stock has now surpassed by 1.50%, marking a breakout. The 50-DMA at ₹40.8 is slightly below today’s price, while the 200-DMA stands at ₹45.1, indicating a bearish longer-term trend but a potential short-term recovery. SAGILITY is currently in the lower third of its 52W range, suggesting room for further upside if momentum continues.
Snapshot: ₹42.77 on 2026-07-27 (chart frozen at publication)
Fundamentals & business context
With a PE of 19.1 and profit margins at 13.0%, SAGILITY’s valuation appears reasonable given its robust revenue CAGR of 19.5%. The market seems to be pricing in future growth rather than current earnings, which is supported by the company’s excellent profit CAGR of 86.1%. Institutional ownership at 20.3% suggests a positive outlook from sophisticated investors. There was no specific NSE catalyst today beyond the SEBI certificate announcement.
Algorithmic scorecard
The overall scorecard reflects a stock with strong fundamental attributes but weaker technical signals. The standout fundamental strengths include a very good revenue CAGR of 19.5% and an excellent profit CAGR of 86.1%, indicating solid growth prospects. Additionally, the stock’s PEG of 0.22 suggests it is undervalued relative to its growth rate, making it an attractive buy on fundamental grounds. On the technical side, the bearish trend signaled by the 50-DMA below the 200-DMA and the stock’s position below both moving averages pose risks. The weak yearly performance, with a 6.8% decline over the last year, further underscores these technical concerns.
Company outlook
Management’s outlook for FY ’27 projects low double-digit growth in constant currency, with an adjusted EBITDA margin guidance between 24% and 25%. They expect seasonal revenues to maintain a 54.5% to 45% split between H2 and H1. The deal pipeline stands at a TCV of ₹570 million to ₹575 million, and despite longer deal timings, management remains qualitatively bullish on client conversations. Strategic plans include repaying remaining debt by the end of FY ’27 and focusing on managed service deals and transformational conversations with clients.
Get all details on SAGILITY — P&L, peers, shareholding and more on TradeAlone.
Health Information Services
Indegene Limited (indgn) Q2 FY27: Revenue Up 39.5% Yoy, H1 USD Revenue Growth at Four-year High
Indegene Limited (INDGN) reports strong Q2 FY27 performance with 39.5% YoY revenue growth and H1 USD revenue hitting a four-year high.
Indegene Limited (INDGN), the strategic operating partner to the global life sciences industry, announced its financial results for the quarter ended September 30, 2026. Indegene’s Q2 FY27 performance showcased a robust revenue growth of 39.5% year-on-year (YoY) in INR, translating to a 27.5% YoY increase in USD. This marks the fifth successive quarter of above 5% sequential growth. The company’s revenue for the quarter stood at ₹11,223 million ($117.5 million), with an EBITDA of ₹1,873 million, marking a 32.0% YoY increase. Moreover, H1 USD revenue growth reached a four-year high, reflecting the company’s sustained deal momentum and favorable industry tailwinds.
Revenue and Profitability
Indegene’s revenue from operations increased significantly to ₹11,223 million, up from ₹8,042 million in the same quarter last year. The company’s EBITDA margin remained stable at 16.7%, despite wage hikes, while the profit after tax (PAT) grew by 10% YoY to ₹1,123 million. This strong performance is attributed to the expansion across top accounts and an increase in the number of $1 million+ clients to 59, including 13 in the $10M+ range.
Growth and Future Outlook
Manish Gupta, Chairman and CEO of Indegene, highlighted the company’s broad-based growth driven by expansion across top accounts and significant deal wins in GenAI-enabled transformation and upstream engagements. Suhas Prabhu, CFO, noted that with a healthy pipeline and sustained deal momentum, Indegene expects growth and margin expansion to come together in the second half. The company anticipates EBITDA to grow faster than revenue in the coming quarters, supported by higher yields on investments and lower amortization.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Indegene Limited
Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.
Indegene gains 17.1% over three months and trades near its 52-week highs. The PEG of 2.45 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock trades at 86% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 17.1% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.
Health Information Services
Sagility Limited (NSE: Sagility) Q2 FY27: 11.9% Y-o-y Constant Currency Organic Growth
Sagility Limited (NSE: SAGILITY) reports Q2 FY27 results with 11.9% Y-o-Y constant currency organic growth and $40.2M ACV.
Sagility Limited (NSE: SAGILITY) has announced its Q2 FY27 results, showcasing robust performance with 11.9% year-over-year constant currency organic growth. The company won $40.2M in ACV from 31 existing clients and 1 new logo, indicating increasing traction in larger deals.
Financial Highlights
The financial performance highlights include a revenue of ₹ 20,321 Million, an Adjusted EBITDA of ₹ 5,353 Million, and an Adjusted PAT of ₹ 3,254 Million. The company’s margin stood at 26.3% for Adjusted EBITDA and 16.0% for Adjusted PAT.
Growth and Expansion
Sagility’s growth is further supported by its acquisition of Chirok Health LLC, which adds specialized CDI and coding capabilities, extending its end-to-end RCM offering and unlocking new growth opportunities. The acquisition is expected to broaden Sagility’s provider footprint and deliver greater client value.
As a result, Sagility continues to strengthen its market position and drive forward-looking growth prospects.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of SAGILITY LIMITED
SAGILITY LIMITED belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.
SAGILITY rises 8.5% over three months, with buying pressure holding steady. The PEG of 0.25 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.5% and profits at 86.1% CAGR. That is strong double-digit growth on both counts. The stock holds at 43% of its 52-week range with RSI at 56. In other words, neither side has a clear edge right now. Revenue grows at 19.5% and profits at 86.1%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of SAGILITY LIMITED.
Health Information Services
Indegene Limited (indgn) Wins Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition
Indegene Limited (INDGN) wins Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition for AI-powered pharma commercialization.
Indegene Limited (INDGN) has been honored with Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition for its outstanding achievements in AI-powered pharma commercialization. This recognition underscores Indegene’s leadership in transforming pharmaceutical commercialization workflows through domain-led AI, knowledge orchestration, and integrated execution.
Recognition Highlights
Frost & Sullivan commends Indegene for its ability to align its AI strategy with the evolving needs of the pharmaceutical industry while executing at scale across commercial, medical, regulatory, safety, analytics, content, and field engagement workflows. The recognition highlights Indegene’s leadership in modernizing complex commercialization processes through domain expertise, technology, data, and execution support.
Innovative Approach
Indegene’s Pharma Operating System (OS) connects business decisions, workflow execution, and intelligence across the enterprise, helping pharmaceutical organizations replace fragmented processes with integrated and adaptive operating models. Its Cortex life sciences-native reasoning engine enables subject matter experts to codify specialized knowledge, creating validated knowledge graphs and guiding AI-enabled workflows.
Forward-Looking Strategy
The company’s commitment to customer experience strengthens its market position by connecting strategy, data, content, execution, and measurable outcomes. Indegene’s platform-agnostic approach allows customers to work in existing technology environments, reducing adoption friction while protecting existing technology investments. This recognition reinforces Indegene’s belief in the next wave of value creation through connecting intelligence, decisions, and execution across the enterprise.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Indegene Limited
Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.
Indegene gains 17.1% over three months and trades near its 52-week highs. The PEG of 2.45 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock trades at 86% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 17.1% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.
-
Consumer Cyclical2 days agoSky GOLD and Diamonds Limited (NSE: Skygold) Q2 and H1 FY27: Revenue at Rs 4,403.45 Crore, PAT Up 111.9%
-
AWL2 days agoAwl Agri Business Limited (AWL) Delivers Strong Q2 FY27 Growth; Revenue Grows 26% to INR 22,202 Crore with Operating Ebitda Up 11% Yoy
-
ACUTAAS2 days agoAcutaas Chemicals Limited (acutaas) Q2 & H1 FY27 Results: Revenue Up 42.7% Yoy, PAT Surges 71.4%
-
DYCL2 days agoDynamic Cables Limited (dycl) Scaling with Strength: Q2 FY27 Results Show Strong Growth
-
Industrials2 days agoNavkar Corporation Limited Announces Q2 FY27 Results: Revenue Up 15%, Ebitda Surges 20%
-
Auto Parts2 days agoSchaeffler India Limited (NSE: Schaeffler) Q3 FY26: Double-digit Growth Across Domestic and Export Businesses
-
Consumer Cyclical2 days agoHuhtamaki India Limited Q3 FY26: Net Sales Surge 23.7%, EBIT Up 18%
-
Consumer Cyclical2 days agoSiyaram Silk Mills Limited Q2 & H1 FY27 Results: Revenue Up 15.1% in Q2 FY27